Advancements in Myasthenia Gravis Treatment: Supporting Access Through Value-Based Care Models

This activity was originally broadcast live as a symposium at AJMC® Day of Education 2022.

Program Description

Myasthenia gravis is a progressive neuromuscular disorder that impacts voluntary muscle movements and can be life-threatening if respiratory function is impaired. The disease course of myasthenia gravis varies, and treatment often needs to be re-evaluated based on disease stage and patient-specific factors, including age and comorbid conditions. Several recently approved and investigational drugs are exploring different mechanisms of action to modify the disease process. Managed care professionals and pharmacists should be familiar with current and emerging therapies and their potential role in treatment plans for the management of patients with myasthenia gravis. It is imperative that managed care pharmacists consider new classes of medications and the impact on total costs when evaluating the potential of emerging treatments for patients with myasthenia gravis. This activity will review new medications and key considerations as well as strategies to improve quality of life and reduce overall health care resource utilization associated with treatments for myasthenia gravis.

Target audience: Managed care pharmacists

Type of activity: Application
Release date: November 1, 2022
Expiration date: November 1, 2023

Time to complete activity: 1.5 hours
Fee: Free

Educational Objectives

At the completion of this activity, participants will be able to:

• Examine the clinical burden of myasthenia gravis and its associated comorbidities.
• Analyze the clinical data and evidence-based approaches in the utilization of new and emerging therapies in the management of myasthenia gravis.
• Explore the associated cost drivers and the managed care considerations in optimizing a value-based approach in the treatment of myasthenia gravis.

Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 1.5 contact hours (0.15 CEU) under the ACPE universal activity number 0290-0000-22-540-H01-P. The activity is available for CE credit through November 1, 2023.

Instructions for Completing the Activity and Receiving CPE Credit

To receive CPE credit, participants must complete the pretest, review the activity in its entirety, complete the posttest, and complete the online activity evaluation. After successful completion of the online activity evaluation, you can submit your credit to CPE Monitor. You may view your credit within 48 hours at www.mycpemonitor.net. All participants must request credit before the activity expiration date. CE credit will not be issued after this date.

Disclosures

The following contributors have no relevant financial relationships with commercial interests to disclose:

Faculty

Nikki Hahn, PharmD, BCACP

Winston Wong, PharmD

Pharmacy Times Continuing Education™ Planning Staff—Jim Palatine, RPh, MBA; Maryjo Dixon, RPh; Dipti Desai, PharmD, MBA, CHCP; Liza Patel, PharmD, RPh; Kylie Ferrentino; Susan Pordon; Brianna Winters; and Chloe Taccetta.

An anonymous peer reviewer was used as part of content validation and conflict resolution. The peer reviewer has no relevant financial relationships with commercial interests to disclose.

Educational Disclaimer
CPE activities are offered solely for educational purposes and do not constitute any form of professional advice or referral. Discussions concerning drugs, dosages, and procedures may reflect the clinical experience of the author(s) or they may be derived from the professional literature or other sources and may suggest uses that are investigational in nature and not approved labeling or indications. Participants are encouraged to refer to primary references or full prescribing information resources.

For questions about this internet CPE activity, please contact:
[email protected]
Privacy Policy and Terms of Use Information:
www.pharmacytimes.org/terms